Objective: This study used real-world data to describe treatment patterns in second-line antidiabetic medication (ADM) regimen (Sulfonylureas, DPP-4 inhibitors, GLP-1 RAs, SGLT2 inhibitors, or TZDs) over a fixed 12 month follow-up period.

Methods: Medical and pharmacy claims were used to identify adult commercial and Medicare Advantage Part D health plan enrollees with T2DM initiating second-line ADMs between 2013-2016. The primary outcome was the first pharmacy claim indicating a change in regimen: switch to a new ADM class; treatment discontinuation (gap ≥30 days); or intensification (≥doubling of dose, adding a new ADM class, or switching to/adding insulin). Patients were classified as adherent if no change was observed.

Results: Of 73,290 study subjects with 2LADM, 53% were Sulfonylurea, 26% were DPP-4, 7% were GLP-1 RA, 9% SGLT2, and 5% TZD. Changes in treatment within 1 year were observed for over 70% of all patients (Table). There was little switching, about 50% discontinued their 2LADM with the highest rate of discontinuation among those receiving GLP-1 RAs and lowest among those receiving TZDs. About 20% of patients intensified medication regimen.

Discussion: The very high rate of observed treatment changes, in particular discontinuation, may indicate that patients face multiple barriers to treatment adherence. Real-world studies can inform patient-centered treatment selection.


S. Pasricha: None. M. Cherupally: None. E. Koep: Employee; Self; UnitedHealth Group. R.T. Ackermann: Research Support; Self; National Institute of Diabetes and Digestive and Kidney Diseases, UnitedHealth Group. C. Aikman: None. A.J. Cooper: None. M. O’Brien: Research Support; Self; UnitedHealth Group. A. Wallia: Research Support; Self; Eli Lilly and Company, Novo Nordisk Inc., UnitedHealth Group. D.T. Liss: None. E.D. Parker: None.


UnitedHealth Services (SP0036847)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.